Pasithea Therapeutics (KTTA) Cash from Operations (2021 - 2024)
Historic Cash from Operations for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$2.4 million.
- Pasithea Therapeutics' Cash from Operations rose 2584.15% to -$2.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$13.9 million, marking a year-over-year decrease of 865.69%. This contributed to the annual value of -$13.9 million for FY2024, which is 865.69% down from last year.
- Pasithea Therapeutics' Cash from Operations amounted to -$2.4 million in Q4 2024, which was up 2584.15% from -$3.1 million recorded in Q3 2024.
- Pasithea Therapeutics' Cash from Operations' 5-year high stood at -$381845.0 during Q1 2021, with a 5-year trough of -$4.6 million in Q3 2022.
- Moreover, its 4-year median value for Cash from Operations was -$3.1 million (2023), whereas its average is -$2.6 million.
- As far as peak fluctuations go, Pasithea Therapeutics' Cash from Operations plummeted by 74267.69% in 2022, and later soared by 2994.09% in 2023.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Cash from Operations stood at -$1.7 million in 2021, then crashed by 82.61% to -$3.2 million in 2022, then decreased by 3.42% to -$3.3 million in 2023, then increased by 25.84% to -$2.4 million in 2024.
- Its last three reported values are -$2.4 million in Q4 2024, -$3.1 million for Q3 2024, and -$4.0 million during Q2 2024.